Ken Griffin Biolife Solutions Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$15.14 - $22.99 $62,074 - $94,259	4,100 Added 54.67%	11,600 $248,000
Q1 2024 May 15, 2024	SELL	$15.35 - $18.82 $102,845 - $126,094	-6,700 Reduced 47.18%	7,500 $139,000
Q4 2023 Feb 14, 2024	SELL	$8.99 - $16.86 $33,263 - $62,382	-3,700 Reduced 20.67%	14,200 $230,000
Q3 2023 Nov 14, 2023	BUY	$10.81 - $22.96 $99,452 - $211,232	9,200 Added 105.75%	17,900 $247,000
Q2 2023 Aug 14, 2023	BUY	$17.19 - $24.34 $77,355 - $109,530	4,500 Added 107.14%	8,700 $192,000
Q1 2023 May 15, 2023	SELL	$17.67 - $26.07 $220,875 - $325,875	-12,500 Reduced 74.85%	4,200 $91,000
Q4 2022 Feb 14, 2023	BUY	$16.95 - $25.07 $283,065 - $418,669	16,700 New	16,700 $303,000

169

46.4M

11.6K

800

Ticker BLFS
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 42,684,400
Market Cap $1.07B
Description
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It of...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.